CA-IKOTEK
20.11.2023 15:01:29 CET | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM), announces with immediate effect the appointment of Mathi Gurusamy as its new Chief Operating Officer (COO). In his new role, Mathi will be responsible for overseeing the company's day-to-day operations, driving strategic initiatives, and contributing to Ikotek's continued growth and success.
Mathi Gurusamy brings a wealth of expertise with over 20 years of experience in the IoT sector and electronic device industry to Ikotek. Prior to joining Ikotek, Mathi held CEO and COO positions at Mobilogix and Telit for the last 15 years. Most recently, Mathi served as Telit Cinterion’s president of its IoT solutions division after the company had acquired Mobilogix in June 2022. Renowned for his adeptness in transforming start-ups into thriving enterprises, Mathi boasts a proven track record. His achievements include securing Fortune 500 companies as clients and cultivating strategic alliances with pivotal partners in the wireless industry.
With a demonstrated ability to effectively manage and drive critical business requirements, Mathi will play a pivotal role in propelling Ikotek's sustained growth and success. His robust leadership skills and strategic vision will help scale Ikotek's business objectives in the US and globally, ensuring a seamless alignment of the company’s services and delivery functions, and continue to deliver significant business impact to Ikotek’s OEM customers globally.
“We are delighted to welcome Mathi Gurusamy to Ikotek as our new COO,” commented Joe Peterson, Ikotek CEO. “His proven track record in the IoT industry and his strategic mindset make him an excellent fit for our organization. Mathi joining Ikotek is a strong endorsement and I am confident that Mathi's leadership will play a key role in advancing Ikotek's mission and ensuring our continued growth."
Mathi Gurusamy expressed his enthusiasm for joining Ikotek, stating, "I am thrilled to be part of the Ikotek team and excited about the opportunity to contribute to the company's impressive growth history. Ikotek has a strong reputation for innovation and commercial excellence across the IoT ecosystem. The ambitious growth vision and strategy is only possible with the massive investment Ikotek and its parent company Quectel has undertaken. I look forward to working with the most talented team in the industry to drive operational efficiency and deliver excellent value to our customers."
As a vital component of the Quectel family and leveraging the significant eco-system synergies of the parent company, Ikotek stands out as the only global ODM exclusively dedicated to IoT. Providing an all-encompassing suite of IoT solutions, Ikotek serves as a comprehensive one-stop-shop covering design and development, hardware construction, testing and verification, product validation, software development, manufacturing, and certification. This integrated approach ensures the delivery of top-tier products and services aimed at minimizing complexity, accelerating time to market, mitigating risks, and optimizing costs. Ikotek's commitment lies in delivering high-quality solutions that resonate with the evolving demands of the IoT landscape.
About Ikotek USA, Inc.
Headquartered in San Diego, California, Ikotek’s core focus is on the enterprise market as it looks to develop ODM solutions to take full advantage of IoT, covering technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120698687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
